These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

445 related articles for article (PubMed ID: 33925565)

  • 1. LAG-3 Blockade with Relatlimab (BMS-986016) Restores Anti-Leukemic Responses in Chronic Lymphocytic Leukemia.
    Sordo-Bahamonde C; Lorenzo-Herrero S; González-Rodríguez AP; Payer ÁR; González-García E; López-Soto A; Gonzalez S
    Cancers (Basel); 2021 Apr; 13(9):. PubMed ID: 33925565
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BTLA/HVEM Axis Induces NK Cell Immunosuppression and Poor Outcome in Chronic Lymphocytic Leukemia.
    Sordo-Bahamonde C; Lorenzo-Herrero S; Gonzalez-Rodriguez AP; R Payer Á; González-García E; López-Soto A; Gonzalez S
    Cancers (Basel); 2021 Apr; 13(8):. PubMed ID: 33917094
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ig-Like Transcript 2 (ILT2) Blockade and Lenalidomide Restore NK Cell Function in Chronic Lymphocytic Leukemia.
    Villa-Álvarez M; Sordo-Bahamonde C; Lorenzo-Herrero S; Gonzalez-Rodriguez AP; Payer AR; Gonzalez-Garcia E; Villa-Álvarez MC; López-Soto A; Gonzalez S
    Front Immunol; 2018; 9():2917. PubMed ID: 30619281
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NK Cells in Chronic Lymphocytic Leukemia and Their Therapeutic Implications.
    Sportoletti P; De Falco F; Del Papa B; Baldoni S; Guarente V; Marra A; Dorillo E; Rompietti C; Adamo FM; Ruggeri L; Di Ianni M; Rosati E
    Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34206399
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relatlimab: a novel drug targeting immune checkpoint LAG-3 in melanoma therapy.
    Su J; Fu Y; Cui Z; Abidin Z; Yuan J; Zhang X; Li R; Zhao C
    Front Pharmacol; 2023; 14():1349081. PubMed ID: 38269271
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting Checkpoint Receptors and Molecules for Therapeutic Modulation of Natural Killer Cells.
    Kim N; Kim HS
    Front Immunol; 2018; 9():2041. PubMed ID: 30250471
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BTLA dysregulation correlates with poor outcome and diminished T cell-mediated antitumor responses in chronic lymphocytic leukemia.
    Sordo-Bahamonde C; Lorenzo-Herrero S; Martínez-Pérez A; Gonzalez-Rodriguez AP; Payer ÁR; González-García E; Aguilar-García C; González-Rodríguez S; López-Soto A; García-Torre A; Gonzalez S
    Cancer Immunol Immunother; 2023 Jul; 72(7):2529-2539. PubMed ID: 37041226
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Deciphering LAG-3: unveiling molecular mechanisms and clinical advancements.
    Martínez-Pérez A; Granda-Díaz R; Aguilar-García C; Sordo-Bahamonde C; Gonzalez S
    Biomark Res; 2024 Oct; 12(1):126. PubMed ID: 39425148
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting immune checkpoints in hematological malignancies.
    Salik B; Smyth MJ; Nakamura K
    J Hematol Oncol; 2020 Aug; 13(1):111. PubMed ID: 32787882
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current Approaches of Immune Checkpoint Therapy in Chronic Lymphocytic Leukemia.
    Taghiloo S; Asgarian-Omran H
    Curr Treat Options Oncol; 2023 Oct; 24(10):1408-1438. PubMed ID: 37561383
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PD-L1 checkpoint blockade prevents immune dysfunction and leukemia development in a mouse model of chronic lymphocytic leukemia.
    McClanahan F; Hanna B; Miller S; Clear AJ; Lichter P; Gribben JG; Seiffert M
    Blood; 2015 Jul; 126(2):203-11. PubMed ID: 25800048
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combinatorial immune checkpoint blockade increases myocardial expression of NLRP-3 and secretion of H-FABP, NT-Pro-BNP, interleukin-1β and interleukin-6: biochemical implications in cardio-immuno-oncology.
    Quagliariello V; Passariello M; Bisceglia I; Paccone A; Inno A; Maurea C; Rapuano Lembo R; Manna L; Iovine M; Canale ML; Scherillo M; Ascierto PA; Gabrielli D; De Lorenzo C; Maurea N
    Front Cardiovasc Med; 2024; 11():1232269. PubMed ID: 38322766
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reactive oxygen species induced by therapeutic CD20 antibodies inhibit natural killer cell-mediated antibody-dependent cellular cytotoxicity against primary CLL cells.
    Werlenius O; Aurelius J; Hallner A; Akhiani AA; Simpanen M; Martner A; Andersson PO; Hellstrand K; Thorén FB
    Oncotarget; 2016 May; 7(22):32046-53. PubMed ID: 27097113
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IL-15 in the Combination Immunotherapy of Cancer.
    Waldmann TA; Dubois S; Miljkovic MD; Conlon KC
    Front Immunol; 2020; 11():868. PubMed ID: 32508818
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recombinant human IL-15 trans-presentation by B leukemic cells from chronic lymphocytic leukemia induces autologous NK cell proliferation leading to improved anti-CD20 immunotherapy.
    Laprevotte E; Voisin G; Ysebaert L; Klein C; Daugrois C; Laurent G; Fournie JJ; Quillet-Mary A
    J Immunol; 2013 Oct; 191(7):3634-40. PubMed ID: 23997218
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD84 regulates PD-1/PD-L1 expression and function in chronic lymphocytic leukemia.
    Lewinsky H; Barak AF; Huber V; Kramer MP; Radomir L; Sever L; Orr I; Mirkin V; Dezorella N; Shapiro M; Cohen Y; Shvidel L; Seiffert M; Herishanu Y; Becker-Herman S; Shachar I
    J Clin Invest; 2018 Dec; 128(12):5465-5478. PubMed ID: 30277471
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expansion of natural killer (NK) and natural killer-like T (NKT)-cell populations derived from patients with B-chronic lymphocytic leukemia (B-CLL): a potential source for cellular immunotherapy.
    Guven H; Gilljam M; Chambers BJ; Ljunggren HG; Christensson B; Kimby E; Dilber MS
    Leukemia; 2003 Oct; 17(10):1973-80. PubMed ID: 14513047
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interleukin-15 enhances rituximab-dependent cytotoxicity against chronic lymphocytic leukemia cells and overcomes transforming growth factor beta-mediated immunosuppression.
    Moga E; Cantó E; Vidal S; Juarez C; Sierra J; Briones J
    Exp Hematol; 2011 Nov; 39(11):1064-71. PubMed ID: 21864486
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunomodulatory Drugs: Immune Checkpoint Agents in Acute Leukemia.
    Knaus HA; Kanakry CG; Luznik L; Gojo I
    Curr Drug Targets; 2017; 18(3):315-331. PubMed ID: 25981611
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glucocorticoid-induced TNFR-related protein (GITR) ligand modulates cytokine release and NK cell reactivity in chronic lymphocytic leukemia (CLL).
    Buechele C; Baessler T; Wirths S; Schmohl JU; Schmiedel BJ; Salih HR
    Leukemia; 2012 May; 26(5):991-1000. PubMed ID: 22064350
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.